Veracyte's Decipher Test Predicts Hormone Therapy Benefit In Phase 3 Prostate Cancer Analysis

(RTTNews) - On Tuesday, Veracyte (VCYT) announced new findings from a retrospective analysis of the Phase 3 NRG/RTOG 0815 trial showing that its Decipher Prostate Genomic Classifier can identify intermediate-risk prostate cancer patients more likely to benefit from adding short-t